PT-141 P41 10mg*10vials

PT-141 (P41) 10mg*10 vials belongs to the CN peptide neuroendocrine and physiological regulation series. It is a basic standard for the synthetic peptide Bremelanotide, matched with a gradient system of high-end PNC27 variants. P41 is a highly bioactive selective MC4R melanocortin receptor agonist with excellent blood-brain barrier permeability, zero immunogenicity, and high biocompatibility. Its stable 10mg standard dose enables mild, precise, and reproducible endogenous neuroendocrine regulation. P41 primarily targets the central melanocortin signaling pathway, pelvic microcirculation, and the hypothalamic metabolic axis, stably regulating neurobehavioral responses, autonomic nervous system function, and energy metabolism balance. It is ideally suited for basic preclinical mechanism validation, low-threshold physiological modeling, and baseline peptide synergistic studies, serving as a core basic research material for standard neuroendocrine physiology research.

Product Functions and Research Value

PT-141 provides four core homeostatic regulatory functions, suitable for basic laboratory research: stable activation of central MC4R receptors, regulating limbic system reward pathways and dopamine release, maintaining normal neurobehavioral and motivational physiological responses; gentle dilation of peripheral pelvic microvessels, optimizing local blood perfusion, stabilizing autonomic nervous system physiological arousal function; regulation of hypothalamic energy metabolism signals, balancing appetite and energy expenditure, supporting basal metabolic homeostasis and physiological processes, for use in weight regulation research; and exerting a mild central nervous system protective effect, alleviating mild neuroinflammation and neurological stress, and stabilizing the central nervous system immune microenvironment. Mild melanocortin pathway dysregulation, poor microcirculation, and basal metabolic imbalance are common causes of physiological sub-health and fluctuations in neuroendocrine function. P41 employs physiologically biomimetic intervention with stable intensity, providing highly reliable baseline experimental data for exploring the basic mechanisms of PT-141, modeling physiological homeostasis, and validating peptide combinations.

Core Product Advantages

1. Stable MC4R Baseline Activation: Highly selectively targets the melanocortin receptor, ensuring stable and moderate pathway activation, avoiding excessive intervention, making it ideal for basic functional validation and control group experiments.

2. Gentle Regulation of Physiological Microcirculation: Gently optimizes pelvic blood perfusion and autonomic nerve stability, suitable for studies on basic physiological circulatory remodeling and autonomic nerve function mechanisms.

3. Maintenance of Basal Metabolic Homeostasis: Stabilizes and balances energy intake and expenditure, improving mild metabolic sub-health conditions, providing a reliable baseline model for basic metabolic physiological research.

4. High Safety and Neuroimmune Stability: Gently alleviates low-grade neuroinflammation, maintains neural microenvironment balance, has good biocompatibility, and does not interfere with immunity, suitable for long-term baseline intervention experiments.

5. Standard High-Purity Process: Employs gradient purification and vacuum freeze-drying technology, ensuring uniform activity and extremely low impurity content, guaranteeing high consistency and reproducibility of basic experimental data.

6. Standard Aseptic Packaging and Quality Control: Packaged in 10-vial dust-free aseptic packs, fully tested for purity by HPLC, and accompanied by a complete Certificate of Account (COA), suitable for routine laboratory basic research and bulk purchases.

PT-141 (P41) 10mg*10 vials belongs to the CN peptide neuroendocrine and physiological regulatory peptide series. It is the **basic standard version** of the Bremerano peptide synthetic peptide, forming a complete tiered product line with the high-end PNC27 premium version. This product is a highly active and selective MC4R melanocortin receptor agonist with excellent blood-brain barrier penetration, zero immunogenicity, and extremely high biocompatibility. The standard 10mg dose allows for gentle, precise intervention with stable activity. Utilizing an endogenous biomimetic mechanism, it targets and regulates the central melanocortin pathway, pelvic microcirculation, and hypothalamic metabolic axis, thereby smoothly regulating neurobehavioral responses, autonomous physiological functions, and energy metabolism homeostasis. It is suitable for basic research scenarios such as preclinical mechanism validation, low-threshold physiological modeling, and baseline synergistic studies of peptides, and is the core standard component of the PT-141 series for basic neuroendocrine physiological research.

Core Uses and Scientific Value of Peptide Drugs

PT-141 (P41) has four core homeostatic uses in basic research.